Tropifexor, a highly potent FXR agonist, produces robust and dose-dependent reductions in hepatic fat and serum alanine aminotransferase in patients with fibrotic NASH after 12 weeks of therapy: FLIGHT-FXR Part C interim results

Autor:	J. White, P. Lopez, Arun J. Sanyal, S. Lamle, J. Vierling, M. Yoneda, D. Lazas, G. Neff, E.J. Lawitz, W. Kim, S. Augustin, S. Hsia, G.G. Boon Bee, A. Sheikh, J. Frias, D. Aizenberg, F. Schaefer, K.J. Lucas, Y. Eguchi, Y. Loeffler, M. Martic, C. Brass
Rok vydání:	2020
Předmět:	Agonist Hepatology medicine.drug_class business.industry Gastroenterology medicine Dose dependence In patient Pharmacology Alanine aminotransferase business
Zdroj:	Digestive and Liver Disease. 52:e38
ISSN:	1590-8658
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::122e51eceba5dbc84a78b90d1a975b7c https://doi.org/10.1016/j.dld.2019.12.129 Zobrazit plný text záznamu Full Text from ScienceDirect